| Secondary |
| Hypertension |
20.8% |
| Rheumatoid Arthritis |
16.7% |
| Stress Urinary Incontinence |
16.7% |
| Urge Incontinence |
16.7% |
| Bronchiectasis |
8.3% |
| Urinary Incontinence |
8.3% |
| Hyperlipidaemia |
4.2% |
| Nasopharyngitis |
4.2% |
| Type 2 Diabetes Mellitus |
4.2% |
|
| Toxic Epidermal Necrolysis |
30.0% |
| Hyperglycaemia |
20.0% |
| Prurigo |
20.0% |
| Eyelid Oedema |
10.0% |
| Pulmonary Haemorrhage |
10.0% |
| Vasculitis |
10.0% |
|
| Concomitant |
| Asthma |
18.1% |
| Product Used For Unknown Indication |
15.6% |
| Drug Use For Unknown Indication |
12.3% |
| Prophylaxis |
8.9% |
| Hypertension |
7.1% |
| Nasopharyngitis |
5.0% |
| Constipation |
3.7% |
| Prostate Cancer Stage Iv |
3.7% |
| Type 2 Diabetes Mellitus |
3.5% |
| Bronchitis |
2.9% |
| Urinary Incontinence |
2.5% |
| Emphysema |
2.3% |
| Cough |
2.1% |
| Chronic Obstructive Pulmonary Disease |
1.9% |
| Gastritis |
1.9% |
| Hypertonic Bladder |
1.9% |
| Multiple Myeloma |
1.7% |
| Prostate Cancer |
1.7% |
| Reflux Oesophagitis |
1.7% |
| Stress Urinary Incontinence |
1.7% |
|
| Subcorneal Pustular Dermatosis |
9.6% |
| Hyperbilirubinaemia Neonatal |
7.2% |
| Rash |
7.2% |
| Bladder Cancer |
6.0% |
| Thrombocytopenia |
6.0% |
| Wheezing |
6.0% |
| Delirium |
4.8% |
| Interstitial Lung Disease |
4.8% |
| Loss Of Consciousness |
4.8% |
| Pseudomembranous Colitis |
4.8% |
| Sudden Death |
4.8% |
| White Blood Cell Count Decreased |
4.8% |
| Abnormal Behaviour |
3.6% |
| Anaphylactic Shock |
3.6% |
| Asthma |
3.6% |
| Blood Potassium Increased |
3.6% |
| Cerebral Infarction |
3.6% |
| Death |
3.6% |
| Drug Ineffective |
3.6% |
| Eosinophil Count Increased |
3.6% |
|
| Interacting |
| Product Used For Unknown Indication |
100.0% |
|
| Drug Interaction |
50.0% |
| Torticollis |
50.0% |
|
